# RSV Neutralizing Antibodies Following Nirsevimab and Palivizumab Dosing

*PRI Rank #20 · Topics and Trends in Most Cited Neonatal Respiratory Health Research Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/neonatal-respiratory-health-research/2026/rank-20*

| Field | Value |
| --- | --- |
| Rank | #20 |
| 18m citations | 28 |
| Journal | PEDIATRICS |
| Year | 2024 |
| DOI | 10.1542/peds.2024-067174 |
| Corresponding authors | Deidre Wilkins, Ulrika Wählby Hamrén |
| Institution | BioPharmaceuticals R&D, United States |

**Ranking page:** [Topics and Trends in Most Cited Neonatal Respiratory Health Research Papers, Class of 2026](https://pri.pepkio.com/top-papers/neonatal-respiratory-health-research/2026)

**Paper link:** [10.1542/peds.2024-067174](https://doi.org/10.1542/peds.2024-067174)

## Topics

nirsevimab · palivizumab · Neutralizing antibodies · Monoclonal antibody · long-acting monoclonal antibodies · RSV F protein · prefusion conformation antibodies · postfusion conformation antibodies · MEDLEY trial · Preterm infants · Congenital heart disease · bronchopulmonary dysplasia · single-dose prophylaxis · monthly dosing regimen · serum antibody concentrations · antibody kinetics · RSV prophylaxis

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Neonatal Respiratory Health Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/neonatal-respiratory-health-research/2026. Accessed 2026-07-22.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```